Privia Health Group, Inc. (PRVA) Stock Competitors & Peer Comparison
See (PRVA) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRVA | $26.94 | +5.44% | 3.2B | 160.81 | $0.16 | N/A |
| GEHC | $65.04 | -0.02% | 29.1B | 14.04 | $4.56 | +0.22% |
| VEEV | $186.24 | +5.69% | 28.8B | 21.30 | $8.33 | N/A |
| GEHCV | $56.00 | -4.08% | 25.5B | N/A | N/A | N/A |
| BTSG | $68.77 | -0.30% | 13.7B | 56.24 | $1.24 | N/A |
| BTSGU | $226.95 | -0.88% | 13.6B | 207.03 | $1.11 | N/A |
| TEM | $61.98 | +6.29% | 10.1B | -115.86 | -$0.50 | N/A |
| SGFY | $30.49 | +0.07% | 8.9B | 70.91 | $0.43 | N/A |
| HQY | $93.76 | +6.77% | 7.6B | 21.10 | $4.28 | N/A |
| HNGE | $85.12 | +4.47% | 6.4B | 42.61 | $1.95 | N/A |
Stock Comparison
PRVA vs GEHC Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, GEHC has a market cap of 29.1B. Regarding current trading prices, PRVA is priced at $26.94, while GEHC trades at $65.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas GEHC's P/E ratio is 14.04. In terms of profitability, PRVA's ROE is +0.03%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, PRVA is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check GEHC's competition here
PRVA vs VEEV Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, VEEV has a market cap of 28.8B. Regarding current trading prices, PRVA is priced at $26.94, while VEEV trades at $186.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas VEEV's P/E ratio is 21.30. In terms of profitability, PRVA's ROE is +0.03%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, PRVA is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check VEEV's competition here
PRVA vs GEHCV Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, PRVA is priced at $26.94, while GEHCV trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas GEHCV's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, PRVA is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check GEHCV's competition here
PRVA vs BTSG Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, BTSG has a market cap of 13.7B. Regarding current trading prices, PRVA is priced at $26.94, while BTSG trades at $68.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas BTSG's P/E ratio is 56.24. In terms of profitability, PRVA's ROE is +0.03%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, PRVA is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check BTSG's competition here
PRVA vs BTSGU Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, BTSGU has a market cap of 13.6B. Regarding current trading prices, PRVA is priced at $26.94, while BTSGU trades at $226.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas BTSGU's P/E ratio is 207.03. In terms of profitability, PRVA's ROE is +0.03%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, PRVA is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check BTSGU's competition here
PRVA vs TEM Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, TEM has a market cap of 10.1B. Regarding current trading prices, PRVA is priced at $26.94, while TEM trades at $61.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas TEM's P/E ratio is -115.86. In terms of profitability, PRVA's ROE is +0.03%, compared to TEM's ROE of -0.70%. Regarding short-term risk, PRVA is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check TEM's competition here
PRVA vs SGFY Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, PRVA is priced at $26.94, while SGFY trades at $30.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SGFY's P/E ratio is 70.91. In terms of profitability, PRVA's ROE is +0.03%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, PRVA is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check SGFY's competition here
PRVA vs HQY Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, HQY has a market cap of 7.6B. Regarding current trading prices, PRVA is priced at $26.94, while HQY trades at $93.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas HQY's P/E ratio is 21.10. In terms of profitability, PRVA's ROE is +0.03%, compared to HQY's ROE of +0.11%. Regarding short-term risk, PRVA is less volatile compared to HQY. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check HQY's competition here
PRVA vs HNGE Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, HNGE has a market cap of 6.4B. Regarding current trading prices, PRVA is priced at $26.94, while HNGE trades at $85.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas HNGE's P/E ratio is 42.61. In terms of profitability, PRVA's ROE is +0.03%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, PRVA is less volatile compared to HNGE. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check HNGE's competition here
PRVA vs RCM Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, RCM has a market cap of 6B. Regarding current trading prices, PRVA is priced at $26.94, while RCM trades at $14.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas RCM's P/E ratio is -102.21. In terms of profitability, PRVA's ROE is +0.03%, compared to RCM's ROE of +0.00%. Regarding short-term risk, PRVA is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check RCM's competition here
PRVA vs TXG Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, TXG has a market cap of 4.9B. Regarding current trading prices, PRVA is priced at $26.94, while TXG trades at $39.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas TXG's P/E ratio is -225.53. In terms of profitability, PRVA's ROE is +0.03%, compared to TXG's ROE of -0.03%. Regarding short-term risk, PRVA is less volatile compared to TXG. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check TXG's competition here
PRVA vs DOCS Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, DOCS has a market cap of 3.9B. Regarding current trading prices, PRVA is priced at $26.94, while DOCS trades at $21.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas DOCS's P/E ratio is 13.54. In terms of profitability, PRVA's ROE is +0.03%, compared to DOCS's ROE of +0.19%. Regarding short-term risk, PRVA is less volatile compared to DOCS. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check DOCS's competition here
PRVA vs ONEM Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, PRVA is priced at $26.94, while ONEM trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas ONEM's P/E ratio is -7.77. In terms of profitability, PRVA's ROE is +0.03%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, PRVA is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check ONEM's competition here
PRVA vs HTFL Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, HTFL has a market cap of 2.5B. Regarding current trading prices, PRVA is priced at $26.94, while HTFL trades at $29.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas HTFL's P/E ratio is -14.60. In terms of profitability, PRVA's ROE is +0.03%, compared to HTFL's ROE of +8.30%. Regarding short-term risk, PRVA is less volatile compared to HTFL. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check HTFL's competition here
PRVA vs PINC Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, PRVA is priced at $26.94, while PINC trades at $28.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas PINC's P/E ratio is 19.22. In terms of profitability, PRVA's ROE is +0.03%, compared to PINC's ROE of -0.02%. Regarding short-term risk, PRVA is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check PINC's competition here
PRVA vs PGNY Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, PGNY has a market cap of 2.3B. Regarding current trading prices, PRVA is priced at $26.94, while PGNY trades at $29.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas PGNY's P/E ratio is 21.04. In terms of profitability, PRVA's ROE is +0.03%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, PRVA is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check PGNY's competition here
PRVA vs WGS Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, WGS has a market cap of 2B. Regarding current trading prices, PRVA is priced at $26.94, while WGS trades at $70.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas WGS's P/E ratio is 80.76. In terms of profitability, PRVA's ROE is +0.03%, compared to WGS's ROE of -0.28%. Regarding short-term risk, PRVA is more volatile compared to WGS. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check WGS's competition here
PRVA vs WGSWW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, WGSWW has a market cap of 2B. Regarding current trading prices, PRVA is priced at $26.94, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas WGSWW's P/E ratio is -0.10. In terms of profitability, PRVA's ROE is +0.03%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, PRVA is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check WGSWW's competition here
PRVA vs NXGN Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, PRVA is priced at $26.94, while NXGN trades at $23.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas NXGN's P/E ratio is -266.00. In terms of profitability, PRVA's ROE is +0.03%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, PRVA is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check NXGN's competition here
PRVA vs TDOC Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, TDOC has a market cap of 1.5B. Regarding current trading prices, PRVA is priced at $26.94, while TDOC trades at $9.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas TDOC's P/E ratio is -9.43. In terms of profitability, PRVA's ROE is +0.03%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, PRVA is less volatile compared to TDOC. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check TDOC's competition here
PRVA vs AGTI Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, PRVA is priced at $26.94, while AGTI trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas AGTI's P/E ratio is -71.79. In terms of profitability, PRVA's ROE is +0.03%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, PRVA is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check AGTI's competition here
PRVA vs OMDA Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, OMDA has a market cap of 1.3B. Regarding current trading prices, PRVA is priced at $26.94, while OMDA trades at $22.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas OMDA's P/E ratio is 313.57. In terms of profitability, PRVA's ROE is +0.03%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, PRVA is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check OMDA's competition here
PRVA vs CERT Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CERT has a market cap of 1B. Regarding current trading prices, PRVA is priced at $26.94, while CERT trades at $6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CERT's P/E ratio is 16.79. In terms of profitability, PRVA's ROE is +0.03%, compared to CERT's ROE of -0.01%. Regarding short-term risk, PRVA is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check CERT's competition here
PRVA vs NUTX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, NUTX has a market cap of 1B. Regarding current trading prices, PRVA is priced at $26.94, while NUTX trades at $183.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas NUTX's P/E ratio is 13.21. In terms of profitability, PRVA's ROE is +0.03%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, PRVA is less volatile compared to NUTX. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check NUTX's competition here
PRVA vs GDRX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, GDRX has a market cap of 998.3M. Regarding current trading prices, PRVA is priced at $26.94, while GDRX trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas GDRX's P/E ratio is 8.73. In terms of profitability, PRVA's ROE is +0.03%, compared to GDRX's ROE of +0.03%. Regarding short-term risk, PRVA is less volatile compared to GDRX. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check GDRX's competition here
PRVA vs CCLDO Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CCLDO has a market cap of 857.3M. Regarding current trading prices, PRVA is priced at $26.94, while CCLDO trades at $27.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CCLDO's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, PRVA is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check CCLDO's competition here
PRVA vs HSTM Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, HSTM has a market cap of 796.1M. Regarding current trading prices, PRVA is priced at $26.94, while HSTM trades at $28.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas HSTM's P/E ratio is 35.86. In terms of profitability, PRVA's ROE is +0.03%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, PRVA is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check HSTM's competition here
PRVA vs EVH Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, EVH has a market cap of 648.5M. Regarding current trading prices, PRVA is priced at $26.94, while EVH trades at $5.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas EVH's P/E ratio is 576.50. In terms of profitability, PRVA's ROE is +0.03%, compared to EVH's ROE of -0.78%. Regarding short-term risk, PRVA is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check EVH's competition here
PRVA vs PHR Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, PHR has a market cap of 636.7M. Regarding current trading prices, PRVA is priced at $26.94, while PHR trades at $10.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas PHR's P/E ratio is 36.79. In terms of profitability, PRVA's ROE is +0.03%, compared to PHR's ROE of +0.03%. Regarding short-term risk, PRVA is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check PHR's competition here
PRVA vs MPLN-WT Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, PRVA is priced at $26.94, while MPLN-WT trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, PRVA is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check MPLN-WT's competition here
PRVA vs CTEV Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CTEV has a market cap of 583M. Regarding current trading prices, PRVA is priced at $26.94, while CTEV trades at $33.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CTEV's P/E ratio is -2.62. In terms of profitability, PRVA's ROE is +0.03%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, PRVA is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check CTEV's competition here
PRVA vs ACCD Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, PRVA is priced at $26.94, while ACCD trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas ACCD's P/E ratio is -3.08. In terms of profitability, PRVA's ROE is +0.03%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, PRVA is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check ACCD's competition here
PRVA vs CCLDP Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CCLDP has a market cap of 566.6M. Regarding current trading prices, PRVA is priced at $26.94, while CCLDP trades at $19.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CCLDP's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, PRVA is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check CCLDP's competition here
PRVA vs SHCR Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, PRVA is priced at $26.94, while SHCR trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SHCR's P/E ratio is -3.76. In terms of profitability, PRVA's ROE is +0.03%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, PRVA is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check SHCR's competition here
PRVA vs NRC Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, NRC has a market cap of 486.1M. Regarding current trading prices, PRVA is priced at $26.94, while NRC trades at $22.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas NRC's P/E ratio is 24.51. In terms of profitability, PRVA's ROE is +0.03%, compared to NRC's ROE of +0.57%. Regarding short-term risk, PRVA is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check NRC's competition here
PRVA vs SOPH Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SOPH has a market cap of 396.6M. Regarding current trading prices, PRVA is priced at $26.94, while SOPH trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SOPH's P/E ratio is -11.10. In terms of profitability, PRVA's ROE is +0.03%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, PRVA is less volatile compared to SOPH. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check SOPH's competition here
PRVA vs SLGC Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, PRVA is priced at $26.94, while SLGC trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SLGC's P/E ratio is -3.04. In terms of profitability, PRVA's ROE is +0.03%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, PRVA is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check SLGC's competition here
PRVA vs SLGCW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, PRVA is priced at $26.94, while SLGCW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, PRVA's ROE is +0.03%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, PRVA is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check SLGCW's competition here
PRVA vs TBRG Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, TBRG has a market cap of 393.1M. Regarding current trading prices, PRVA is priced at $26.94, while TBRG trades at $26.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas TBRG's P/E ratio is 9.36. In terms of profitability, PRVA's ROE is +0.03%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, PRVA is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check TBRG's competition here
PRVA vs MPLN Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, PRVA is priced at $26.94, while MPLN trades at $23.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas MPLN's P/E ratio is -0.23. In terms of profitability, PRVA's ROE is +0.03%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, PRVA is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check MPLN's competition here
PRVA vs SLP Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SLP has a market cap of 370M. Regarding current trading prices, PRVA is priced at $26.94, while SLP trades at $18.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SLP's P/E ratio is 17.78. In terms of profitability, PRVA's ROE is +0.03%, compared to SLP's ROE of -0.49%. Regarding short-term risk, PRVA is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check SLP's competition here
PRVA vs TRHC Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, PRVA is priced at $26.94, while TRHC trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas TRHC's P/E ratio is -4.27. In terms of profitability, PRVA's ROE is +0.03%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, PRVA is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check TRHC's competition here
PRVA vs SMFR Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, PRVA is priced at $26.94, while SMFR trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SMFR's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, PRVA is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check SMFR's competition here
PRVA vs SPOK Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SPOK has a market cap of 213.9M. Regarding current trading prices, PRVA is priced at $26.94, while SPOK trades at $10.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SPOK's P/E ratio is 17.07. In terms of profitability, PRVA's ROE is +0.03%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, PRVA is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check SPOK's competition here
PRVA vs SY Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SY has a market cap of 190.3M. Regarding current trading prices, PRVA is priced at $26.94, while SY trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SY's P/E ratio is -4.39. In terms of profitability, PRVA's ROE is +0.03%, compared to SY's ROE of -0.16%. Regarding short-term risk, PRVA is less volatile compared to SY. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check SY's competition here
PRVA vs AMWL Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, AMWL has a market cap of 154.2M. Regarding current trading prices, PRVA is priced at $26.94, while AMWL trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas AMWL's P/E ratio is -1.78. In terms of profitability, PRVA's ROE is +0.03%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, PRVA is less volatile compared to AMWL. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check AMWL's competition here
PRVA vs HCAT Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, HCAT has a market cap of 147M. Regarding current trading prices, PRVA is priced at $26.94, while HCAT trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas HCAT's P/E ratio is 9.95. In terms of profitability, PRVA's ROE is +0.03%, compared to HCAT's ROE of -1.00%. Regarding short-term risk, PRVA is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check HCAT's competition here
PRVA vs CPSI Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, PRVA is priced at $26.94, while CPSI trades at $9.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CPSI's P/E ratio is -183.80. In terms of profitability, PRVA's ROE is +0.03%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, PRVA is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check CPSI's competition here
PRVA vs AUGX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, PRVA is priced at $26.94, while AUGX trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas AUGX's P/E ratio is -4.99. In terms of profitability, PRVA's ROE is +0.03%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, PRVA is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check AUGX's competition here
PRVA vs OPRX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, OPRX has a market cap of 107.3M. Regarding current trading prices, PRVA is priced at $26.94, while OPRX trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas OPRX's P/E ratio is 5.25. In terms of profitability, PRVA's ROE is +0.03%, compared to OPRX's ROE of +0.05%. Regarding short-term risk, PRVA is less volatile compared to OPRX. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check OPRX's competition here
PRVA vs CCLD Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CCLD has a market cap of 90.1M. Regarding current trading prices, PRVA is priced at $26.94, while CCLD trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CCLD's P/E ratio is 6.42. In terms of profitability, PRVA's ROE is +0.03%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, PRVA is less volatile compared to CCLD. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check CCLD's competition here
PRVA vs DH Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, DH has a market cap of 87.7M. Regarding current trading prices, PRVA is priced at $26.94, while DH trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas DH's P/E ratio is 3.20. In terms of profitability, PRVA's ROE is +0.03%, compared to DH's ROE of -0.67%. Regarding short-term risk, PRVA is less volatile compared to DH. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check DH's competition here
PRVA vs FORA Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, FORA has a market cap of 67.8M. Regarding current trading prices, PRVA is priced at $26.94, while FORA trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas FORA's P/E ratio is -24.11. In terms of profitability, PRVA's ROE is +0.03%, compared to FORA's ROE of -0.17%. Regarding short-term risk, PRVA is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check FORA's competition here
PRVA vs ONMD Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, ONMD has a market cap of 37.9M. Regarding current trading prices, PRVA is priced at $26.94, while ONMD trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas ONMD's P/E ratio is -4.65. In terms of profitability, PRVA's ROE is +0.03%, compared to ONMD's ROE of +0.90%. Regarding short-term risk, PRVA is less volatile compared to ONMD. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check ONMD's competition here
PRVA vs SNCE Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, PRVA is priced at $26.94, while SNCE trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SNCE's P/E ratio is -0.27. In terms of profitability, PRVA's ROE is +0.03%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, PRVA is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check SNCE's competition here
PRVA vs AKLI Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, PRVA is priced at $26.94, while AKLI trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas AKLI's P/E ratio is -0.71. In terms of profitability, PRVA's ROE is +0.03%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, PRVA is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check AKLI's competition here
PRVA vs SHLT Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, PRVA is priced at $26.94, while SHLT trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SHLT's P/E ratio is -3.87. In terms of profitability, PRVA's ROE is +0.03%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, PRVA is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check SHLT's competition here
PRVA vs SHCRW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, PRVA is priced at $26.94, while SHCRW trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, PRVA's ROE is +0.03%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, PRVA is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check SHCRW's competition here
PRVA vs ONMDW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, ONMDW has a market cap of 30.7M. Regarding current trading prices, PRVA is priced at $26.94, while ONMDW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas ONMDW's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to ONMDW's ROE of +0.90%. Regarding short-term risk, PRVA is less volatile compared to ONMDW. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check ONMDW's competition here
PRVA vs EUDA Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, EUDA has a market cap of 27.1M. Regarding current trading prices, PRVA is priced at $26.94, while EUDA trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas EUDA's P/E ratio is -2.66. In terms of profitability, PRVA's ROE is +0.03%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, PRVA is less volatile compared to EUDA. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check EUDA's competition here
PRVA vs STRM Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, PRVA is priced at $26.94, while STRM trades at $5.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas STRM's P/E ratio is -2.40. In terms of profitability, PRVA's ROE is +0.03%, compared to STRM's ROE of -0.32%. Regarding short-term risk, PRVA is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check STRM's competition here
PRVA vs RNLX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, PRVA is priced at $26.94, while RNLX trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas RNLX's P/E ratio is -0.33. In terms of profitability, PRVA's ROE is +0.03%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, PRVA is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check RNLX's competition here
PRVA vs LIFW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, PRVA is priced at $26.94, while LIFW trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas LIFW's P/E ratio is -0.02. In terms of profitability, PRVA's ROE is +0.03%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, PRVA is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check LIFW's competition here
PRVA vs BEATW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, BEATW has a market cap of 20.6M. Regarding current trading prices, PRVA is priced at $26.94, while BEATW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas BEATW's P/E ratio is -0.06. In terms of profitability, PRVA's ROE is +0.03%, compared to BEATW's ROE of -10.34%. Regarding short-term risk, PRVA is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check BEATW's competition here
PRVA vs BBLN Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, PRVA is priced at $26.94, while BBLN trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas BBLN's P/E ratio is -0.04. In terms of profitability, PRVA's ROE is +0.03%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, PRVA is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check BBLN's competition here
PRVA vs ETAO Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, PRVA is priced at $26.94, while ETAO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas ETAO's P/E ratio is -0.01. In terms of profitability, PRVA's ROE is +0.03%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, PRVA is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check ETAO's competition here
PRVA vs BFRG Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, BFRG has a market cap of 8.3M. Regarding current trading prices, PRVA is priced at $26.94, while BFRG trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas BFRG's P/E ratio is -1.31. In terms of profitability, PRVA's ROE is +0.03%, compared to BFRG's ROE of -2.18%. Regarding short-term risk, PRVA is less volatile compared to BFRG. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check BFRG's competition here
PRVA vs HLTH Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, PRVA is priced at $26.94, while HLTH trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas HLTH's P/E ratio is -0.02. In terms of profitability, PRVA's ROE is +0.03%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, PRVA is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check HLTH's competition here
PRVA vs SCNX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SCNX has a market cap of 5.4M. Regarding current trading prices, PRVA is priced at $26.94, while SCNX trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SCNX's P/E ratio is -0.14. In terms of profitability, PRVA's ROE is +0.03%, compared to SCNX's ROE of -0.00%. Regarding short-term risk, PRVA is less volatile compared to SCNX. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check SCNX's competition here
PRVA vs UPH-WT Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, PRVA is priced at $26.94, while UPH-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, PRVA is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check UPH-WT's competition here
PRVA vs UPH Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, PRVA is priced at $26.94, while UPH trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas UPH's P/E ratio is -0.07. In terms of profitability, PRVA's ROE is +0.03%, compared to UPH's ROE of -1.05%. Regarding short-term risk, PRVA is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check UPH's competition here
PRVA vs PEAR Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, PRVA is priced at $26.94, while PEAR trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas PEAR's P/E ratio is -0.08. In terms of profitability, PRVA's ROE is +0.03%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, PRVA is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check PEAR's competition here
PRVA vs PEARW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, PRVA is priced at $26.94, while PEARW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas PEARW's P/E ratio is -0.00. In terms of profitability, PRVA's ROE is +0.03%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, PRVA is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check PEARW's competition here
PRVA vs MGRX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, MGRX has a market cap of 3.9M. Regarding current trading prices, PRVA is priced at $26.94, while MGRX trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas MGRX's P/E ratio is -0.28. In terms of profitability, PRVA's ROE is +0.03%, compared to MGRX's ROE of -1.21%. Regarding short-term risk, PRVA is more volatile compared to MGRX. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check MGRX's competition here
PRVA vs OTRK Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, PRVA is priced at $26.94, while OTRK trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas OTRK's P/E ratio is -0.02. In terms of profitability, PRVA's ROE is +0.03%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, PRVA is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check OTRK's competition here
PRVA vs HCTI Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, HCTI has a market cap of 2M. Regarding current trading prices, PRVA is priced at $26.94, while HCTI trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas HCTI's P/E ratio is -0.02. In terms of profitability, PRVA's ROE is +0.03%, compared to HCTI's ROE of -0.68%. Regarding short-term risk, PRVA is less volatile compared to HCTI. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check HCTI's competition here
PRVA vs VSEE Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, VSEE has a market cap of 1.9M. Regarding current trading prices, PRVA is priced at $26.94, while VSEE trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas VSEE's P/E ratio is -0.22. In terms of profitability, PRVA's ROE is +0.03%, compared to VSEE's ROE of -115.71%. Regarding short-term risk, PRVA is less volatile compared to VSEE. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check VSEE's competition here
PRVA vs CMAX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, PRVA is priced at $26.94, while CMAX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CMAX's P/E ratio is -0.00. In terms of profitability, PRVA's ROE is +0.03%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, PRVA is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check CMAX's competition here
PRVA vs ACON Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, ACON has a market cap of 1.5M. Regarding current trading prices, PRVA is priced at $26.94, while ACON trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas ACON's P/E ratio is -0.27. In terms of profitability, PRVA's ROE is +0.03%, compared to ACON's ROE of -0.54%. Regarding short-term risk, PRVA is less volatile compared to ACON. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check ACON's competition here
PRVA vs BFRGW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, BFRGW has a market cap of 1.5M. Regarding current trading prices, PRVA is priced at $26.94, while BFRGW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas BFRGW's P/E ratio is -1.00. In terms of profitability, PRVA's ROE is +0.03%, compared to BFRGW's ROE of -2.18%. Regarding short-term risk, PRVA is more volatile compared to BFRGW. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check BFRGW's competition here
PRVA vs VSEEW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, VSEEW has a market cap of 1.5M. Regarding current trading prices, PRVA is priced at $26.94, while VSEEW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas VSEEW's P/E ratio is -0.06. In terms of profitability, PRVA's ROE is +0.03%, compared to VSEEW's ROE of -115.71%. Regarding short-term risk, PRVA is more volatile compared to VSEEW. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check VSEEW's competition here
PRVA vs LIFWZ Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, PRVA is priced at $26.94, while LIFWZ trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, PRVA is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check LIFWZ's competition here
PRVA vs EUDAW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, EUDAW has a market cap of 1.1M. Regarding current trading prices, PRVA is priced at $26.94, while EUDAW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas EUDAW's P/E ratio is 0.04. In terms of profitability, PRVA's ROE is +0.03%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, PRVA is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check EUDAW's competition here
PRVA vs MSPRZ Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, PRVA is priced at $26.94, while MSPRZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, PRVA is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check MSPRZ's competition here
PRVA vs WORX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, PRVA is priced at $26.94, while WORX trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas WORX's P/E ratio is -1.17. In terms of profitability, PRVA's ROE is +0.03%, compared to WORX's ROE of -0.65%. Regarding short-term risk, PRVA is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check WORX's competition here
PRVA vs KERNW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, PRVA is priced at $26.94, while KERNW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas KERNW's P/E ratio is -0.00. In terms of profitability, PRVA's ROE is +0.03%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, PRVA is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check KERNW's competition here
PRVA vs KERN Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, PRVA is priced at $26.94, while KERN trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas KERN's P/E ratio is -0.01. In terms of profitability, PRVA's ROE is +0.03%, compared to KERN's ROE of -0.17%. Regarding short-term risk, PRVA is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check KERN's competition here
PRVA vs LIFWW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, PRVA is priced at $26.94, while LIFWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas LIFWW's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, PRVA is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check LIFWW's competition here
PRVA vs ZCMD Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, ZCMD has a market cap of 36.5K. Regarding current trading prices, PRVA is priced at $26.94, while ZCMD trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas ZCMD's P/E ratio is -0.02. In terms of profitability, PRVA's ROE is +0.03%, compared to ZCMD's ROE of -0.32%. Regarding short-term risk, PRVA is less volatile compared to ZCMD. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check ZCMD's competition here
PRVA vs CMAXW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, PRVA is priced at $26.94, while CMAXW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CMAXW's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, PRVA is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check CMAXW's competition here
PRVA vs ACONW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, ACONW has a market cap of 11.5K. Regarding current trading prices, PRVA is priced at $26.94, while ACONW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas ACONW's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to ACONW's ROE of -0.54%. Regarding short-term risk, PRVA is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check ACONW's competition here
PRVA vs NAVA Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, NAVA has a market cap of 0. Regarding current trading prices, PRVA is priced at $26.94, while NAVA trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas NAVA's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to NAVA's ROE of +0.15%. Regarding short-term risk, Volatility data is not available for a full comparison. PRVA has daily volatility of 4.80 and NAVA has daily volatility of N/A.Check NAVA's competition here
PRVA vs AFFX Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, AFFX has a market cap of 0. Regarding current trading prices, PRVA is priced at $26.94, while AFFX trades at $14.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas AFFX's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to AFFX's ROE of +0.03%. Regarding short-term risk, PRVA is more volatile compared to AFFX. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check AFFX's competition here
PRVA vs CHNGU Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CHNGU has a market cap of 0. Regarding current trading prices, PRVA is priced at $26.94, while CHNGU trades at $73.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CHNGU's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to CHNGU's ROE of -0.05%. Regarding short-term risk, PRVA is more volatile compared to CHNGU. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check CHNGU's competition here
PRVA vs MTBC Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, MTBC has a market cap of 0. Regarding current trading prices, PRVA is priced at $26.94, while MTBC trades at $3.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas MTBC's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to MTBC's ROE of +0.17%. Regarding short-term risk, PRVA is less volatile compared to MTBC. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check MTBC's competition here
PRVA vs CERN Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CERN has a market cap of 0. Regarding current trading prices, PRVA is priced at $26.94, while CERN trades at $94.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CERN's P/E ratio is 55.84. In terms of profitability, PRVA's ROE is +0.03%, compared to CERN's ROE of +0.14%. Regarding short-term risk, PRVA is more volatile compared to CERN. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check CERN's competition here
PRVA vs CHNG Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, CHNG has a market cap of 0. Regarding current trading prices, PRVA is priced at $26.94, while CHNG trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas CHNG's P/E ratio is -152.72. In terms of profitability, PRVA's ROE is +0.03%, compared to CHNG's ROE of -0.05%. Regarding short-term risk, PRVA is more volatile compared to CHNG. This indicates potentially higher risk in terms of short-term price fluctuations for PRVA.Check CHNG's competition here
PRVA vs KURIU Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, KURIU has a market cap of 0. Regarding current trading prices, PRVA is priced at $26.94, while KURIU trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas KURIU's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to KURIU's ROE of +1.06%. Regarding short-term risk, PRVA is less volatile compared to KURIU. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check KURIU's competition here
PRVA vs SMFRW Comparison July 2026
PRVA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRVA stands at 3.2B. In comparison, SMFRW has a market cap of 0. Regarding current trading prices, PRVA is priced at $26.94, while SMFRW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRVA currently has a P/E ratio of 160.81, whereas SMFRW's P/E ratio is N/A. In terms of profitability, PRVA's ROE is +0.03%, compared to SMFRW's ROE of -0.28%. Regarding short-term risk, PRVA is less volatile compared to SMFRW. This indicates potentially lower risk in terms of short-term price fluctuations for PRVA.Check SMFRW's competition here